Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.38 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.37 |
| ▸ | NR1I3 | Q14994 | 5/20 | 0.35 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | RORC | P51449 | 5/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17827851 | 0.87 | SIRT2 (0.38) | SIRT2SIRT1HCRTR1HCRTR2NR1I3 | |
| SCHEMBL17819981 | 0.86 | CA1 (0.34) | CA12CA1CA9CA2CA4 | |
| SCHEMBL17827864 | 0.81 | CA12 (0.39) | SIRT2SIRT1HCRTR1HCRTR2NR1I3 | |
| SCHEMBL17827833 | 0.79 | SIRT2 (0.40) | SIRT2SIRT1HCRTR1HCRTR2NR1I3 | |
| SCHEMBL22426061 | 0.79 | CA12 (0.48) | NR1I3CA12CA1CA9RORC | |
| SCHEMBL17831354 | 0.78 | AAK1 (0.35) | HCRTR1HCRTR2 | |
| SCHEMBL17827863 | 0.77 | SIRT2 (0.40) | SIRT2SIRT1HCRTR1HCRTR2NR1I3 | |
| SCHEMBL3165587 | 0.75 | ATM (0.38) | SIRT2SIRT1HCRTR1HCRTR2NR1I3 | |
| SCHEMBL31061614 | 0.74 | ALDH1A1 (0.48) | CA12CA1CA9RORCCYP2C19 | |
| SCHEMBL65972 | 0.74 | ALDH1A1 (0.48) | CA12CA1CA9RORCCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9586951-B2 | Morpholine derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2017-03-07 | — | — | US | disclosed |
| US-9586951-B2 | Morpholine derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2017-03-07 | — | — | US | disclosed |
| US-20160168139-A1 | NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2016-06-16 | — | — | US | disclosed |
| US-20160168139-A1 | NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168139-A1 | NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF | PRMT7, RBBP7, RER1 | SIRT2 1326/4885SIRT1 1475/4885HCRTR1 320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.